EQT exits from Galderma via record block trade

EQT completed a final sell-down of ~34.0 million Galderma shares via the largest sponsor-backed block trade in history, raising ~CHF 4.9 billion in aggregate with EQT VIII receiving ~CHF 1.3 billion. Under EQT ownership Galderma grew revenue from $2.8bn (2018) to $5.2bn (2025), organic growth accelerating to ~18% in 2025 and EBITDA rising from $520m to $1.2bn, while EQT has realized ~CHF 21bn (~$26bn) since the IPO. The placement was done via accelerated bookbuilding with major banks as joint bookrunners, marking the largest value-creation exit in EQT's history and likely to have a meaningful stock-specific impact.

Analysis

A large, sponsor-driven liquidity event in a high-growth specialty healthcare name acts as a fresh valuation benchmark for the dermatology sub-sector and for private equity returns in healthcare. That benchmark tends to compress the risk premium investors assign to similar growth stories (higher correlation to cyclicality, lower idiosyncratic premium) within a 1–3 month window while the market digests free-float changes and the new peer comps.

For the sponsor / GP, crystallizing a major outcome materially de-risks vintage performance and shortens the fundraising narrative: expect a tangible uplift in credibility with LPs that should accelerate deal activity and increase competition for platform assets over the next 12–24 months. That acceleration raises buyout multiples in the space and increases the probability of follow-on strategic M&A (strategic buyers and larger PE consortia competing for roll-ups) within 6–18 months.

Second-order winners include contract manufacturers, specialty distributors and platform consolidators who can scale smaller dermatology brands — they will see acquisition funding become more available and multiples re-rate ahead of buyer consolidation. Key tail risks are clinical/regulatory setbacks in novel therapeutics, reimbursement pushback, and a reversal in private capital liquidity; any of these could reverse the sector rerating within 3–12 months.

Consensus is likely underweight the persistence of public-market volatility after a sponsor exit: the initial price move often overshoots and then mean-reverts as fundamentals (product cadence, net retention) reassert themselves over 9–18 months. That asymmetry creates a tradeable window where short-term supply-driven weakness can be paired against longer-term fundamental strength for convex payoffs.

Key Decisions for Investors

• Long EQT (6–12 months): buy EQT stock or a 9–12 month call spread (long ITM call, sell OTM call) sized 2–4% NAV to capture re-rating as realized exits boost track record. Target 30–40% upside; max loss limited to premium (expect 1:3 downside control if spread used).
• Short GALD tactical (0–3 months): establish a small short via 1–3 month ATM puts or a short equity position sized 1–2% NAV to capture immediate supply-driven downside/volatility. Target 15–25% move and trim on stabilization; place stop if option premium doubles or stock rallies >15% on volume (cut loss quickly).
• Pair trade (6–12 months): long EQT / short GALD (equal notional) to isolate re-rating of sponsor/GP performance vs. company-specific float pressure. This reduces directional market risk; expect pair to converge with a target spread return of 20–35% and a stop at 12–15% adverse movement in the pair.
• Convex long GALD (12–24 months): if sold into weakness, buy 12–24 month LEAP calls or a backspread to capture long-term product cadence and consolidation upside while limiting upfront capital. Size 1–3% NAV as a tail position — asymmetric payoff if fundamentals continue to outpace peers.